255 ExPRESSTM: An accelerated process for the manufacture of KSQ-001, a CRISPR/Cas9-edited eTILTM product

Sharon Lin; Leila Williams; Mitali Ghose; Hugh Gannon; Conor Calnan; Angelina Pizzo; Pei-Lun Kao; Mallory Brady; Katri Sofjan; Anne Dodson; Sol Shenker; Michael Schlabach; Fiona Sharp; Frank Stegmeier; Micah Benson; Karrie Wong

doi:10.1136/jitc-2022-SITC2022.0255

Article info

PDF

Regular and Young Investigator Award Abstracts

Cell Therapies

255 ExPRESS^TM: An accelerated process for the manufacture of KSQ-001, a CRISPR/Cas9-edited eTIL^TM product

Free

Authors

Sharon Lin KSQ Therapeutics, Cambridge, MA, USA PubMed articles Google scholar articles
Leila Williams KSQ Therapeutics, Cambridge, MA, USA PubMed articles Google scholar articles
Mitali Ghose KSQ Therapeutics, Cambridge, MA, USA PubMed articles Google scholar articles
Hugh Gannon KSQ Therapeutics, Cambridge, MA, USA PubMed articles Google scholar articles
Conor Calnan KSQ Therapeutics, Cambridge, MA, USA PubMed articles Google scholar articles
Angelina Pizzo KSQ Therapeutics, Cambridge, MA, USA PubMed articles Google scholar articles
Pei-Lun Kao KSQ Therapeutics, Cambridge, MA, USA PubMed articles Google scholar articles
Mallory Brady KSQ Therapeutics, Cambridge, MA, USA PubMed articles Google scholar articles
Katri Sofjan KSQ Therapeutics, Cambridge, MA, USA PubMed articles Google scholar articles
Anne Dodson KSQ Therapeutics, Cambridge, MA, USA PubMed articles Google scholar articles
Sol Shenker KSQ Therapeutics, Cambridge, MA, USA PubMed articles Google scholar articles
Michael Schlabach KSQ Therapeutics, Cambridge, MA, USA PubMed articles Google scholar articles
Fiona Sharp KSQ Therapeutics, Cambridge, MA, USA PubMed articles Google scholar articles
Frank Stegmeier KSQ Therapeutics, Cambridge, MA, USA PubMed articles Google scholar articles
Micah Benson KSQ Therapeutics, Cambridge, MA, USA PubMed articles Google scholar articles
Karrie Wong KSQ Therapeutics, Cambridge, MA, USA PubMed articles Google scholar articles

Citation

Lin S, Williams L, Ghose M, et al

255 ExPRESS^TM: An accelerated process for the manufacture of KSQ-001, a CRISPR/Cas9-edited eTIL^TM product

Journal for ImmunoTherapy of Cancer 2022;10:doi: 10.1136/jitc-2022-SITC2022.0255

Publication history

First published November 7, 2022.

Online issue publication

April 26, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Main menu

Authors

Citation

Publication history

Request permissions

Copyright information

Log in using your username and password

Main menu

Log in using your username and password

You are here

Authors

Citation

Publication history

Request permissions

Copyright information

Read the full text or download the PDF:

Log in using your username and password